Study title |
NCT.no |
Key inclusion and exclusion criteria |
Drug |
Control group |
Primary and secondary endpoint |
A Single-arm, Phase II Study of Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in Resectable Non-small Cell Lung Cancer (NSCLC) |
NCT02716038 |
Eligible patients were aged 18 years or older and had resectable American Joint Committee on Cancer-defined stage IB-IIIA non-small-cell lung cancer, an ECOG performance status of 0–1, and a history of smoking exposure |
Atezolizumab; carboplatin; nab-paclitaxel |
Carboplatin + nab-paclitaxel |
The primary endpoint was major pathological response, defined as the presence of 10% or less residual viable tumour at the time of surgery |
Randomized, Open-label, Controlled Phase III Trial Comparing Pembrolizumab-platinum Based Chemotherapy Combination With Pembrolizumab Monotherapy in First Line Treatment of Non-small-cell Lung Cancers (NSCLC) With PDL1 Expression ≥50% |
NCT04547504 |
Advanced NSCLC molecularly defined by a PDL1 expression ≥50% of tumour cells and no EGFR mutations or ALK rearrangement |
Pembrolizumab; cisplatin; carboplatin AUC |
Pembrolizumab alone |
The primary endpoint was PFS. The secondary endpoints were PFS, iPFS, ORR, OS, DOT, DOR, AE and AESI |
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Non-small Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)-China Extension Study |
NCT04676412 |
No prior systemic therapy for their metastatic NSCLC whose tumors has a PD-L1 TPS ≥1% |
Lenvatinib; pembrolizumab |
Pembrolizumab + placebo |
The primary endpoints were PFS and OS. The secondary endpoints were ORR, AE, GHS, QoL, EORTC and TTD |
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Non-small Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007) |
NCT03829332 |
No prior systemic therapy for their metastatic NSCLC whose tumors has a PD-L1 TPS ≥1% |
Lenvatinib; pembrolizumab |
Pembrolizumab + placebo |
The primary endpoints were PFS and OS. The secondary endpoints were ORR, AE, GHS, QoL, EORTC and TTD |
A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS) |
NCT02504372 |
Stage IB/II–IIIA NSCLC who have undergone surgical resection |
Pembrolizumab |
Placebo |
The primary endpoint was DFS. The secondary endpoints were OS and LCSS |
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867) |
NCT03924869 |
Medically inoperable Stage I or IIA NSCLC |
Pembrolizumab; SBRT |
SBRT + placebo |
The primary endpoints were EFS and OS. The secondary endpoints were TDDM, AE and EORTC QLQ-LC13/-C30 SCORE |
A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008) |
NCT03976375 |
Metastatic NSCLC and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti-PD-1/PD-L1 |
Pembrolizumab; lenvatinib; docetaxel |
Docetaxel |
The primary endpoints were OS and PFS. The secondary endpoints were ORR, DOR, AE, EORTC QLQ-LC13/-C30 SCORE and TTD in EORTC QLQ-LC13 Cough (Item 31) Scale Score |
A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789) |
NCT03515837 |
Adults with the following types of TKI-resistant, EGFR-mutated, metastatic NSCLC tumors: (I) TKI-failures (including osimertinib [TAGRISSO®] failure) with T790M-negative mutation tumors, (II) T790M-positive mutation tumors with prior exposure to osimertinib, and (III) first-line osimertinib failure regardless of T790M mutation status |
Pembrolizumab; pemetrexed; carboplatin; cisplatin |
Placebo + pemetrexed + carboplatin+ cisplatin |
The primary endpoints were OS and PFS. The secondary endpoints were ORR, DOR, AE, EORTC QLQ-LC13/-C30 SCORE and TTD in the EORTC Questionnaire Composite Endpoint of Cough, Chest Pain or Dyspnea |
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer |
NCT03631706 |
Advanced NSCLC with high PD-L1-tumor expression, with no EGFR mutation or ALK translocation |
M7824; pembrolizumab |
Pembrolizumab |
The primary endpoints were OS and PFS. The secondary endpoint were TEAEs, NCI-CTCAE, CR, PR and Immunogenicity |
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3–4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671) |
NCT03425643 |
Resectable stage II, IIIA, and resectable IIIB (T3-4N2) NSCLC |
Pembrolizumab; cisplatin; gemcitabine; pemetrexed |
NAC + neoadjuvant/adjuvant placebo |
The primary endpoints were EFS and OS. The secondary endpoints were mPR rate, pCR rate, AE and EGHS/QoL SCORE |
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1) |
NCT03631199 |
Previously untreated locally advanced or metastatic non-squamous and squamous NSCLC subjects |
Canakinumab; pembrolizumab; carboplatin; cisplatin; paclitaxel; nab-paclitaxel; pemetrexed |
Canakinumab matching-placebo |
The primary endpoint were DLTs, PFS and OS. The secondary endpoints were ORR, DCR, DOR and TTR |
A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006) |
NCT03829319 |
Adults with metastatic nonsquamous NSCLC |
Pembrolizumab; carboplatin; cisplatin; pemetrexed; lenvatinib |
Pemetrexed + platinum chemotherapy + pembrolizumab + placebo |
The primary endpoints were DLTs, AES, PFS and OS. The secondary endpoints were ORR, DOR and EORTC QLQ-LC13/-C30 SCORE |
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer |
NCT04194944 |
Participants with RET fusion-positive non-squamous NSCLC that has spread to other parts of the body |
Selpercatinib; carboplatin; cisplatin; pemetrexed; pembrolizumab |
Pemetrexed with or without pembrolizumab |
The primary endpoint was PFS. The secondary endpoints were ORR, DCR, PFS, OS, DOR and Time to Deterioration of Pulmonary Symptoms |
A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407) |
NCT03875092 |
Chinese adults with first line metastatic squamous NSCLC |
Pembrolizumab; paclitaxel; nab-paclitaxel; carboplatin |
Chemotherapy |
The primary endpoints were PFS and OS. The secondary endpoints were ORR, DOR and AE |
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) |
NCT03976362 |
Have not received prior systemic treatment for their advanced/metastatic NSCLC |
Pembrolizumab; carboplatin; paclitaxel; nab-paclitaxel; olaparib |
Pembrolizumab + carboplatin + taxane + olaparib placebo |
The primary endpoints were PFS and OS. The secondary endpoints were AE, EORTC QLQ-C30/LC13 score and TTD in EORTC QLQ-C30/LC13 |
PD-1 Inhibitors and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer |
NCT03774732 |
Patients with advanced (stage IIIB/IV) NSCLC |
Radiotherapy; pembrolizumab; chemotherapy |
Pembrolizumab + chemotherapy |
The primary endpoint was OS. The secondary endpoints were Tumour response, PFS, Acute/Late toxicities and Quality of life of the patients using EORTC-QLQ-C30 |
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs. Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) |
NCT04380636 |
Participants with unresectable, locally advanced NSCLC |
Pembrolizumab; olaparib; etoposide; carboplatin; cisplatin; paclitaxel; pemetrexed; thoracic radiotherapy; durvalumab |
Chemoradiation→durvalumab |
The primary endpoints were PFS and OS. The secondary endpoints were AE, DOR, ORR and EORTC-QLQ-C30 score |
A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs. Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer |
NCT03976323 |
Advanced NSCLC with no EGFR mutation, ALK translocation or ROS1-directed therapy |
Pembrolizumab; pemetrexed; carboplatin; cisplatin; olaparib |
Pembrolizumab + pemetrexed + platinum therapy + pemetrexed |
The primary endpoints were PFS and OS. The secondary endpoints were AE, EORTC-QLQ-C30 score and TTD in EORTC QLQ-LC13 Cough (Item 31) Scale Score |
A Randomized Trial of Consolidative Immunotherapy With vs. Without Thoracic Radiotherapy and/or Stereotactic Body Radiation Therapy (SBRT) After First-Line Systemic Therapy for Metastatic NSCLC |
NCT03867175 |
Stage IV NSCLC with no EGFR mutation, ROS1 or ALK gene rearrangements |
Stereotactic body radiation therapy; pembrolizumab |
Body radiation therapy |
The primary endpoint was PFS. The secondary endpoints were Time of Progression, AE, Rate of Failure and Number of Participants with New Sites of Disease |
A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 ≥50% |
NCT03515629 |
Patients with advanced squamous or non-squamous NSCLC whose tumors express PD-L1 in ≥50% of tumor cells |
REGN2810/ipi; REGN2810/chemo/ipi; Pembrolizumab |
Pembrolizumab |
The primary endpoint was PFS. The secondary endpoints were OS, ORR, TEAEs, SAEs, DLTs and Quality of life |
QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care vs. Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC. |
NCT03520686 |
Stage III/IV advanced or metastatic NSCLC |
N-803; pembrolizumab; carboplatin; nab-paclitaxel |
Control A: pembrolizumab; Control B: carboplatin + nab-paclitaxel or paclitaxel + pembrolizumab; control c: cisplatin or carboplatin + pembrolizumab + pemetrexed |
The primary endpoint was PFS. The secondary endpoints were OS, ORR, PFS, DCR and Quality of life |
A Randomized, Open-Label, Phase 3 Study of Pralsetinib Versus Standard of Care for First Line Treatment of RET Fusion-positive, Metastatic Non-Small Cell Lung Cancer |
NCT04222972 |
Patients with RET fusion-positive metastatic NSCLC who have not previously received systemic anticancer therapy for metastatic disease |
Pralsetinib; carboplatin; cisplatin; pemetrexed; pembrolizumab; gemcitabine |
Platinum doublet with or without pembrolizumab |
The primary endpoint was PFS. The secondary endpoints were OS, ORR, AE, DCR and CBR |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum Based Chemotherapy With Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer |
NCT04475939 |
Participants with Stage IIIB or IV NSCLC who have achieved Stable disease (SD), Partial response (PR), or complete response (CR) following completion of platinum-based first-line induction chemotherapy with pembrolizumab |
Niraparib; pembrolizumab |
Placebo + pembrolizumab |
The primary endpoints were PFS and OS. The secondary endpoints were AE, TTD in Lung Symptoms and TPP |
A Randomized Non-inferiority Trial Evaluating the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors |
NCT04157985 |
Patients who have disease stability to stop treatment at 1 year or continue treatment until disease progression |
Pembrolizumab; nivolumab; atezolizumab; ipilimumab |
Continue Treatment with PD-1/PD-L1 inhibitor |
The primary endpoint was Time to next treatment. The secondary endpoints were OS, irAEs and BOR |
An Open-label, Randomized Phase III Study of Early Switch Maintenance vs. DElayed Second-line Nivolumab in Advanced Stage Squamous Non Small-cell Lung Cancer (NSCLC) Patients After Standard First-line Platinum-based Chemotherapy - EDEN Trial |
NCT03542461 |
Patients with advanced stage squamous NSCLC without immunotherapy |
Nivolumab |
Best supportive care |
The primary endpoint was OS. The secondary endpoints were PFS, TTF, OSind and PFSind |
A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs. CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) |
NCT04026412 |
Participants with untreated locally advanced NSCLC |
Nivolumab; ipilimumab; durvalumab |
Nivolumab/durvalumab + CCRT |
The primary endpoints were PFS and OS. The secondary endpoints were AE, ORR and TTR |
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen |
NCT02066636 |
Advanced or metastatic NSCLC (subjects with non-squamous histology must be tested for EGFR mutations and ALK rearrangement) |
Nivolumab |
|
The primary endpoint was AEs. The secondary endpoint were AEs and Median time to onset and median time to resolution |
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) |
NCT02477826 |
Stage IV or recurrent NSCLC, with no prior systemic anticancer therapy |
Nivolumab; ipilimumab; carboplatin; cisplatin; gemcitabine; pemetrexed; paclitaxel |
Platinum doublet chemotherapy |
The primary endpoints were PFS and OS. The secondary endpoints were ORR and LCSS |
Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs. Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy |
NCT02864251 |
Patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR TKI therapy |
Nivolumab; ipilimumab; pemetrexed; cisplatin; carboplatin |
Platinum doublet chemotherapy |
The primary endpoint was PFS. The secondary endpoints were PFS, ORR, OS and DOR |
Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC |
NCT02998528 |
Early stage IB-IIIA, operable NSCLC |
Nivolumab; cisplatin; vinorelbine; gemcitabine; docetaxel; pemetrexed; carboplatin; paclitaxel; ipilimumab |
Platinum doublet chemotherapy |
The primary endpoints were EFS and pCR. The secondary endpoints were OS, MPR and TTDM |
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) |
NCT01642004 |
Subjects with squamous cell NSCLC, after failure of prior platinum-based chemotherapy |
Nivolumab; docetaxel |
Docetaxel |
The primary endpoint was OS. The secondary endpoints were PFS, ORR, OS and TTR |
Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly (More Than 70 Years Old) Patients With Advanced Non-small Cell Lung Cancer |
NCT03351361 |
Patients already have metastatic disease and a systemic, palliative treatment is the primary therapeutic option |
Nivolumab; ipilimumab; chemotherapy |
Chemotherapy |
The primary endpoint was OS. The secondary endpoints were PFS, ORR, Quality of life score and PD-L1 |
An Open Label, Safety Study of Participants With Non-Small Cell Lung Cancer Receiving Second-Line Nivolumab Monotherapy in Asia |
NCT03195491 |
Patients in Asia with NSCLC who are treated with Nivolumab monotherapy as a second line or third line treatment |
Nivolumab |
|
The primary endpoint was AE. The secondary endpoints were AE and Laboratory test abnormalities |
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE |
NCT03906071 |
Patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy |
Nivolumab; sitravatinib; docetaxel |
Docetaxel |
The primary endpoint was OS. The secondary endpoints were AEs, PFS and ORR |
A Randomized Phase 3 Trial Comparing Continuation Nivolumab-Ipilimumab Doublet Immunotherapy Until Progression Versus Observation in Treatment-naive Patients With PDL1-positive Stage IV Non-Small Cell Lung Cancer (NSCLC) After Nivolumab-Ipilimumab Induction Treatment |
NCT03469960 |
Stage IV NSCLC, with no prior systemic anticancer therapy, PD-L1 tumor content ≥1% and <50% |
Ipilimumab; nivolumab |
Standard treatment:6 months of treatment by nivolumab + ipilimumab then nivolumab + ipilimumab then in case of progression platinum-based doublet recommended |
The primary endpoint was PFS. The secondary endpoints were OS, PFS and Quality of life |
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers |
NCT02595944 |
Patients with stage IB–IIIA NSCLC |
Nivolumab |
No intervention |
The primary endpoints were DFS and OS. The secondary endpoint was AE |
Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR) -Strategic Alliance: BMS |
NCT03391869 |
Patients with stage IV NSCLC |
Radiation therapy; local consolidation therapy; nivolumab; ipilimumab |
Ipilimumab + nivolumab |
The primary endpoint was OS. The secondary endpoints were PFS, TANM and Quality of life |
A Phase III Clinical Trial of Adjuvant Chemotherapy vs. Chemoimmunotherapy for Stage IB-IIIA Completely Resected Non-small Cell Lung Cancer (NSCLC) Patients. |
NCT04564157 |
Stage IB–IIIA, completely resected, NSCLC patients |
Carboplatin; paclitaxel; nivolumab |
Carboplatin + paclitaxel |
The primary endpoint was DFS. The secondary endpoints were OS and AE |
A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-IIIB Non-small Cell Lung Cancer |
NCT04025879 |
Early-stage NSCLC with no prior systemic anti-cancer treatment |
Nivolumab; carboplatin; cisplatin; paclitaxel; pemetrexed; docetaxel |
Neoadj. Plac. + Pt-based doublet chemo followed by Adj.Plac. |
The primary endpoint was EFS. The secondary endpoints were OS, pCR, MPR and AE |
A Multicenter, Randomized, Double-Blind Trial in Subjects With Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52) |
NCT03117049 |
Stage IIIB/IV or recurrent non-squamous NSCLC unsuitable for radical radiation |
ONO-4538; carboplatin; paclitaxel; bevacizumab |
Placebo group |
The primary endpoint was PFS. The secondary endpoints were OS, PFS, ORR and AE |